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Background: The impact of anti-TNF, corticosteroid and analgesic therapy on inflammation and pain was evaluated
in a novel mono-arthritic multi-flare rat Streptococcal Cell Wall (SCW) model using Etanercept, Dexamethasone and
Buprenorphine.
Methods: Multiple flares of arthritis were induced with an intra-articular injection of SCW in the hind ankle on day 1,
followed by intravenous challenges on days 21 and 42. Inflammation and pain were monitored in the hind paws.
Cytokine profiling, cell phenotyping, bioluminescence imaging and histopathological evaluation were also performed.
Results: Local injection of SCW caused a rapid onset of inflammation and pain in the injected ankle which resolved
within 4 days (Flare 1). Intravenous injection 20 days after sensitization resulted in an increase in ankle diameter and
pain, which partially resolved in 8 days (Flare 2). The subsequent intra-venous injection in the same animals 14 days
after resulted in a more chronic disease with inflammation and pain persisting over a period of 10 days (Flare 3).
In Flare 2, therapeutic administration of Dexamethasone inhibited paw swelling (95%; P<0.001) and pain (55%;
P<0.05). Therapeutic administration of Buprenorphine inhibited pain (80%; P<0.001) without affecting paw swelling
(0%). Prophylactic administration of Etanercept in Flare 2 inhibited paw swelling (≥60%; P<0.001) and pain by
≥30%. Expression of IL-1β, IL-6, MCP-1 and CINC was reduced by >50% (P<0.001). Treatment with Etanercept in
Flare 3 inhibited paw swelling by 60% (P<0.001) and pain by 25%. Prior treatment with Etanercept in Flare 2 followed
by re-administration in Flare 3 led to a complete loss in the efficacy of Etanercept. Systemic exposure of Etanercept
corroborated with lack of efficacy. Dexamethasone inhibited inflammation and pain in both Flares 2 and 3 (P<0.001).
Conclusions: We established a novel multi-flare SCW arthritis model enabling drug intervention in different stages of
disease. We show for the first time the evaluation of inflammation and pain simultaneously in this model. Etanercept
and Dexamethasone inhibited inflammation, pain and proinflammatory cytokines in this model. Taken together, this
model facilitates the assessment of anti-rheumatic agents targeting inflammation and pain in the multiple flare
paradigm and offers a powerful tool for drug discovery.
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Rheumatoid arthritis (RA) is a chronic inflammatory
disease of unknown etiology that affects about 1% of the
population in industrialized countries [1]. It is associated
with disability, pain and significantly affects quality of
life [2]. If left untreated, RA can ultimately lead to joint
destruction, systemic bone loss, increased risk of frac-
tures and other comorbidities [3,4]. The pathogenesis of
RA comprises a complex inflammatory response, involv-
ing macrophages, synoviocytes, T cells, B cells, proin-
flammatory cytokines and autoantibodies, causing joint
damage and resulting in erosion of bone and cartilage [5,6].
Currently, there are well established therapeutic options
for treating RA, namely Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Disease Modifying Anti-Rheumatic
Drugs (DMARDs) that include biologic agents targeting
cytokines, T lymphocytes and B cells [7-9]. More recently,
targeting kinases with small molecule inhibitors for
inflammatory disorders has been an area of intense focus
for research [10]. This has led to the approval of the oral
DMARD Tofacitinib, a pan-Janus kinase inhibitor, for the
treatment of moderate to severe RA [11,12].
The synovial joints of RA patients have higher levels
of several proinflammatory cytokines and chemokines,
the most predominant of which are: TNF, IL-1β, IL-6
and MCP-1 [13-16]. TNF is a proinflammatory cytokine
that plays a central role in the pathogenesis of RA,
resulting in destruction of bone and cartilage [17,18].
Therapies targeted toward neutralizing TNF have shown
substantial efficacy in RA patients and in preclinical
models as well [19,20]. Although anti-TNF therapy is a
preferred strategy for the treatment of RA, some patients
do not respond to anti-TNF treatment, whereas others
lose the initial response over time [21]. One of the reasons
for the loss of efficacy could be attributed to the gener-
ation of anti-drug antibodies (ADA) to the anti-TNF
agent, that might reduce or neutralize the therapeutic
effect [22].
In RA, the release of numerous proinflammatory media-
tors such as cytokines IL-6, IL-1β and TNF, result in an
increased sensitivity to pain [23,24]. It has also been
shown that thresholds for pain and pressure are decreased
in the affected joints of patients with RA [25]. The mani-
festation of pain is a result of both excitatory and inhibi-
tory signals that are processed by higher brain centers
[26]. Most anti-rheumatic therapeutics are effective in
controlling inflammation, however further investigation
is required, in order to identify novel anti-rheumatic
agents that can simultaneously inhibit inflammation
and pain [27]. The impact of treatment for rheumatoid
arthritis is typically evaluated using American College
of Rheumatology (ACR) scores, of which one of the
critical components is the evaluation of pain in addition
to inflammation [28]. Furthermore, Heiberg et al. [29]suggested that an improvement in pain reduction was an
area of high priority and managing pain can significantly
improve the quality of life for RA patients. The reduction
of inflammation alone is only a partially effective strategy
in the treatment of RA, as patients still present with
chronic joint pain [23]. Consequently, management of
pain is critical for any effective treatment paradigm
for RA [27].
Animal models of Rheumatoid Arthritis have played a
major role in our understanding of the mechanisms of
disease pathophysiology and have supported drug discov-
ery leading to identification of novel therapies [30-32].
Preclinical models of arthritis share many immunological,
clinical and histological characteristics with human RA,
however, none of them capture all the facets of the human
disease [33]. Several preclinical models of arthritis such as
Adjuvant Induced Arthritis (AA) and Collagen Induced
Arthritis (CIA) are widely used in drug discovery [30].
These models are poly-arthritic, involving multiple joints
and the disease phenotype is chronic and progressive
unlike the flares and remissions observed in RA [34].
Streptococcal Cell Wall (SCW) is a rodent model of
arthritis that effectively captures repeated remission
and flaring phenotype, similar to RA [35]. A single
intra-peritoneal injection of SCW extract PeptidoGlycan-
PolySaccharide (PG-PS 10s) induces inflammation in per-
ipheral joints with repeated phases of self-reactivating
flares resembling RA [36]. However, the recurrence of
reactivation is unpredictable and often difficult to control,
hence this model was modified by Schwab et al. [37], in
order to synchronize the flares. The modified SCW model
is induced by a local intra-articular (i.a.) injection of SCW
extract PG-PS 100p in the hind tarsus (flare 1) followed by
a systemic intravenous (i.v.) challenge (flare 2). The model
is characterized by a mono-arthritic multi-flare phenotype
of two distinct remissions and flares. Inflammation is
limited only to the sensitized joint with no detectable
involvement of other joints, unlike other preclinical
models of arthritis [38]. Demonstrating efficacy in animal
models of pain is an important step in identifying novel
anti-rheumatic agents that can effectively target inflamma-
tion and pain in the clinic [23]. Therefore, in addition to
inflammation we have evaluated paw withdrawal thresh-
old as a surrogate for pain. We applied the established
von-Frey assay, previously described for mechanical pain
assessment in preclinical animal models and in RA pa-
tients alike [25,39]. Although, evaluation of inflammation
and pain have been previously reported in other preclin-
ical models of arthritis [40-42], to our knowledge, this is
the first report investigating the clinically relevant read-
outs such as pain and inflammation simultaneously in
the SCW model. Furthermore, we extended the model
by inducing an additional flare by re-challenging the
rats with an additional systemic intravenous injection of
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mation and mechanical pain in the previously sensitized
joint. In addition, we evaluated the impact of anti-TNF,
corticosteroid and analgesic therapy using etanercept,
dexamethasone and buprenorphine to understand the
translatability of this model in a clinical setting. The
mechanisms leading to pathogenesis in the model were
further delineated by histopathological evaluation, cyto-
kine profiling, cell phenotyping and bioluminescence
imaging of the arthritic joint.
Here we report distinct temporal profiles of inflamma-
tion and mechanical pain in the rat SCW model that
have not been previously described. Moreover, we show
that TNF could potentially be a key driver of inflamma-
tion and could in part contribute to the onset of pain in
this model.
Methods
Animal use and care
Female Lewis rats (6–8 week old; Harlan Laboratories,
Indianapolis, Indiana, USA) were acclimated for 5 days
prior to the experiments and were housed under stand-
ard conditions. Female Lewis rats were used in all of
these experiments due to their established susceptibility
to various mediators of inflammation [43]. These experi-
ments were conducted in accordance with federal animal
care guidelines and all procedures were reviewed by the
Institutional Animal Care and Use Committee (IACUC)
of Merck Inc.
Induction and assessment of the SCW model
For the induction of SCW arthritis we modified the
protocol that was originally described by Schwab et al.
[37]. For initial model development studies the rats
were allocated to four different groups and were ad-
ministered with either saline (non-arthritic; negative
control), 2.5 μg, 5 μg or 10 μg of SCW extract Peptido
Glycan-PolySaccharide (PG-PS) 100p (BD Biosciences,
Franklin Lakes, NJ, USA) by intra-articular (i.a.) injec-
tion into the tarsal joint to induce flare 1. On day 21,
three weeks after the initial i.a. injection, rats were chal-
lenged intravenously (i.v.) with either saline (non-arthritic;
negative control) or 100 μg PG-PS 100p (SCW) to induce
flare 2. Based on the data from our initial studies the
5 μg dose of SCW via i.a. injection followed by 100 μg
of SCW via i.v. injection was used for all subsequent ex-
periments. In later experiments, an additional third flare
(Flare 3) was induced by re-challenging the rats on day
42 with an i.v. injection of 100 μg of SCW. Inflamma-
tion and mechanical pain were assessed by measuring
ankle diameter (surrogate for inflammation) using preci-
sion mechanical calipers and withdrawal threshold (surro-
gate for pain) using electronic von-Frey assay through
the course of study.Withdrawal threshold: electronic von-Frey for assessing
mechanical pain
Electronic von-Frey (Somedic Sales AB, Horby, Sweden)
analysis was performed using methods described previ-
ously [39]. The rats were placed on an elevated grid rack
under individual polycarbonate cages allowing easy access
to the plantar foot surface. The tip of the von-Frey probe
was brought up gently to touch the center of the paw
plantar surface, and pressure was gradually increased
perpendicularly at a rate of approximately 5 g/sec. The
von-Frey probe records increasing pressure (grams)
values, until a paw withdrawal reaction by the rat was
observed. The mean of two consecutive responses per
rat was recorded and used for data analysis.
Dosing paradigm in flare 2
SCW induced arthritic rats were randomly assigned to
specific treatment groups and their baseline ankle diam-
eter and withdrawal threshold values were recorded. Test
article interventions were by oral gavage or subcutaneous
injection either in a Prophylactic (P) or Therapeutic (T)
regimen. In the prophylactic treatment regimen, com-
pounds were administered once daily for 10 days starting
on day 20 (1 day prior to SCW intravenous challenge)
ending on day 29. The therapeutic treatment regimen
entailed compound administration once daily for 8 days
starting on day 22 (1 day post SCW intravenous challenge)
ending on day 29. Non-arthritic and SCW control rats
received vehicle (PEG 400:10% Tween 80 [1:9]) orally.
Etanercept (Enbrel; Amgen Inc., Thousand Oaks, CA,
USA) was purchased from Myoderm Limited, Norristown,
PA, USA and was reconstituted in bacteriostatic water
as per manufacturer’s instructions. Etanercept (subcu-
taneous (s.c.); 0.25 or 1 mg/kg/day) was administered
either in prophylactic or therapeutic regimens. Rats in the
dexamethasone group (Sigma Aldrich, St. Louis, MO,
USA) received dexamethasone (per oral (p.o.); 0.3 mg/kg/
day) suspended in (PEG 400:10% Tween 80 [1:9]). Bupre-
norphine (Sigma Aldrich) groups received buprenorphine
(p.o.; 0.05 mg/kg/day) suspended in saline in the thera-
peutic regimen. The dosing of compounds for all groups
was stopped on day 29.
Dosing paradigm in flares 2 and 3
In certain experiments an additional flare (Flare 3) was
induced in all rats following flare 1 and flare 2. The rats
were randomly assigned to two cohorts, cohort 1 and
cohort 2, prior to compound administration. In cohort 1,
SCW induced rats were assigned to one of the following
treatment groups: etanercept (s.c.; 1 mg/kg/day), human
IgG1 isotype control (s.c.; 1 mg/kg/day) or dexamethasone
(p.o.; 0.3 mg/kg/day) and were dosed in the prophylactic
regimen from day 21 to day 29 in flare 2. Subsequently,
these rats had a drug washout period of 14 days and were
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human IgG1 isotype control (s.c.; 1 mg/kg/day) and dexa-
methasone (p.o.; 0.3 mg/kg/day) from days 41 to 51
(flare 3). In cohort 2, the rats were treated with etaner-
cept (s.c.; 1 mg/kg/day), human IgG1 isotype control (s.c.;
1 mg/kg/day) or dexamethasone (p.o.; 0.3 mg/kg/day) in
flare 3 only. Non-arthritic and SCW control rats received
vehicle (bacteriostatic water) as a subcutaneous injection.
In vivo BioLuminescence imaging (BLI)
Bioluminescence Imaging was performed using IVIS
Spectrum imaging system (Perkin Elmer, Waltham, MA,
USA) following methods described previously [44,45].
Drug naïve non-arthritic controls and SCW induced rats
were injected subcutaneously with a single injection of
200 mg/kg of Luminol (Sigma Aldrich) suspended in
phosphate-buffered saline (PBS). Image analysis was per-
formed using Living Image 4.0 (Perkin Elmer, Waltham,
MA, USA), and average radiance (photons/second) was
measured by placing a circular region of interest (ROI)
centered over the SCW or non-arthritic hind tarsal joint
with a second ROI placed over the contralateral tarsal
joint for comparison.
Histopathology
All the rats designated for histomorphologic assessment
(post-flare 2 only) survived to scheduled study termin-
ation. At necropsy, left hindlimbs were excised distal to
the hip, and fixed in 10% Neutral Buffered Formalin.
The knee (with attached distal femur and proximal tibia)
and hind paw (with ankle, distal tibia, tarsal bones,
metatarsal and phalangeal joints) were decalcified in
Immunocal (Decal Chemical Co, Suffern, NY, USA) for
approximately 20 hours (knee) or 51 hours (hind paw),
trimmed longitudinally (midsagittal) and placed back in
decalcification solution for 2 hours (hindpaws only).
After washing, the knee and hind paws from each rat were
processed, sectioned, and stained with Hematoxylin &
Eosin for subsequent microscopic evaluations. A veterin-
ary pathologist scored the sections of knee and hind paws
for inflammation, pannus formation, cartilage destruction,
periosteal bone formation, and/or bone resorption, using
severity grades: 1 = very slight, 2 = slight, 3 =moderate,
4 =marked, 5 = severe. The histomorphologic assessment
was subsequently submitted for peer review by a second
veterinary pathologist.
Cytokine analysis
Ankle tissue (whole joints including synovium, bone and
surrounding tissues) were excised post euthanasia and
flash frozen in liquid nitrogen. The ankle tissue was
pulverized and treated in a co-mixture of cell extraction
solution, phosphatase and protease inhibitors. The tissue
was homogenized and the supernatant was processed forcytokine expression, using Milliplex MAP 27-plex rat
cytokine/chemokine magnetic bead panel (EMD Milli-
pore, Billerica, MA, USA) on a Luminex FlexMAP 3D
instrument (Luminex, Austin, TX, USA) following manu-
facturer instructions. Values for samples below the lower
limit of the standard curve were set at the value of the
lowest standard for analysis. All samples were run in
duplicate or triplicate and the values are reported for
technical replicates.Cellular phenotyping
Lymph nodes or ankle tissues were pooled for each
group, prior to flow cytometry analysis. Cells from the
lymph nodes were mechanically harvested to generate a
single cell suspension in media. Ankle tissue was minced
and digested with 0.44 U/mL Liberase enzyme and 9 U/
mL dnase and made into a single cell suspension. All
the antibodies (clone name in parenthesis) were pur-
chased from BD Biosciences unless noted otherwise.
The entire lymph node and ankle tissues were digested
in 1800uL of the buffer, 80 uL of which was analyzed by
flow cytometry to ascertain the cell population distribu-
tion in the lysate. The absolute numbers were quantified
by back calculating to account for the whole lysate.
Cells were blocked with anti-CD32 (D34-485) Fc block,
followed by addition of either of two staining antibody
cocktails: cocktail 1 containing CD45 V450 (OX-1),
CD45RA FITC (OX-33), CD3 APC (1F4), CD4 pecy7
(OX-35), CD8 percp (OX-8), and cocktail 2 containing
CD45 V450, CD172 PE (OX-41), anti-granulocyte FITC
(HIS48), CD4 peCy7, CD163 Alexa Fluor 647 (ED2)
(AbD Serotec, Kidlington, Oxford, UK). Total T cells
were derived from CD45+, CD3+, CD45RA- cells from
the cocktail 1 staining condition. This population was
further analyzed for CD4+ and CD8+ cells. Neutrophils
were derived from CD45+, anti gran hi, CD172+,
CD163- cells from the cocktail 2 staining condition. T
cell and neutrophil counts were analyzed relative to the
starting leukocytes counts (CD45+ cells) for each assay.Compound exposure (PK) of etanercept
Circulating levels of etanercept in rat serum were ascer-
tained on the Gyrolab xP instrument (Gyros AB, Uppsala,
Sweden) equipped with Bioaffy 200 CD. The capture anti-
body used was Biotinylated-anti-TNFaRII mouse IgG2a
(Clone # 22235) (R and D Systems, Minneapolis, MN,
USA) and the detection antibody used was DyLight
650-conjugated anti-human IgG1 Fc Rabbit monoclonal
antibody (Clone # H26-10) (Abcam, Cambridge, MA,
USA). Standard curve was prepared in 50% naïve female
lewis rat serum in Rexxip A (Gyros AB) with the linear
range from 0.457 to 1000 ng/ml. Etanercept was quanti-
fied with Gyrolab Evaluator software.
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Data were analyzed and plotted using Graphpad Prism 5
(GraphPad Software Inc., La Jolla, CA, USA). Percentage
inhibition for individual treatment groups are calculated
by normalizing Area Under the Curve (AUC) for paw
swelling and withdrawal threshold by fitting SCW vehicle
groups to 100% and non-arthritic controls to 0%. AUC
normalization was performed using the formula: ((Treat-
ment – Non-Arthritic)/(SCW – Non-Arthritic)) * 100.
AUC was calculated over time for flare 2 from days 21–29
and for flare 3 from days 42 to 51. Statistical significance
(P value <0.05) was determined by two way analysis of
variance for inflammation and mechanical pain analysis or
by one way analysis of variance for cytokine and Biolumin-
escence imaging analysis followed by Bonferroni post-tests.
Comparisons were made for all drug treated groups versus
non-arthritic treated with appropriate vehicle (represented
by *) or SCW treated with appropriate vehicle (represented
by ^) groups. All values are expressed as mean ± SEM,
unless otherwise noted. Relative change of ankle diam-
eter and withdrawal threshold in SCW injected rats as
compared to non-arthritic controls is represented by Δ.
Results
Establishment of the SCW mono-arthritic multi-flare model
Increasing doses (2.5 μg, 5 μg and 10 μg) of SCW were
administered via i.a. injection into the hind tarsal joint
on day 1 (Figure 1A). The local injection resulted in a
marked increase in ankle diameter that peaked on day 2
(24 hr post i.a. injection), followed by a continued de-
cline in ankle diameter by day 4 in all 3 dose groups
(flare 1). To confirm delivery of the antigen to local joint
space, hind limbs of the rats injected with 5 μg SCW,
were assessed by BLI imaging for myeloperoxidase activ-
ity using luminol 6 hr post SCW sensitization. Negative
controls included contralateral paws or hind limbs from
non-arthritic controls. Significantly higher biolumines-
cence at the site of SCW injection (1.1 * 106 ± 1.7 * 105
photons/second; P < 0.001) was detected compared to the
contralateral and non-arthritic control ankles, confirming
local delivery of SCW to the ankle joint (Figure 1B). The
rats from the SCW injected groups were challenged on
day 21 via a systemic i.v. injection of 100 μg SCW. A dose
dependent increase in ankle diameter was observed in the
2.5 μg, 5 μg and 10 μg SCW treated groups (Δ0.65, Δ2.7,
Δ3 mm, respectively) compared to the non-injected con-
trols with a maximal response between days 24–25. This
was followed by a gradual decrease in hind paw swelling
over a period of 4 days (flare 2). The dose combination of
5 μg SCW at sensitization and 100 μg SCW at challenge
resulted in robust and reproducible ankle edema in both
flares 1 and 2 compared to contralateral and non-arthritic
control ankles. This dose combination was used for all
further experiments.Cellular phenotyping in ankle tissue and lymph nodes
Based on the previously established role of neutrophils
and T cells in the pathogenesis of the model [46], we
phenotyped these cells in the local ankle joint and lymph
nodes by flow cytometry. We observed an increase in
neutrophils and T cells in the injected ankle joint 24 hr
post induction of flare 1 compared to non-arthritic con-
trols. The infiltrating T cells in the local joint were
primarily CD4+, however, CD8+ T cells were not ob-
served at this time-point. In flare 2 at 24 hr post induc-
tion, a lower number of neutrophils were observed in
the local joint compared to flare 1. Interestingly, at
this time point we detected a two fold increase in the
number of T cells in the popliteal lymph node, proximal
to the site of sensitization compared to non-arthritic
controls (Table 1).
Histopathological evaluation
Histomorphologic assessment was limited to the hind
limbs post flare 2 rats only euthanized on day 29
(Figure 1C). SCW-injected tarsal joints had significant
injury, localized primarily to the tibio-tarsal and proximal
intertarsal joints and associated tibial and tarsal bones,
characterized by slight inflammation and slight to moder-
ate pannus formation (associated with overt bone loss). A
few rats in this group also had slight focal periosteal bone
formation. The remaining hindlimb joints (stifle proximal
to the injected paw, and contralateral hind paw and stifle)
had no histomorphologic findings. Hind paws from the
non-arthritic control rats served as negative controls, and
there were no histomorphologic findings.
Kinetics of cytokine expression in local sensitized ankle
joint
Next, the kinetics of cytokine and chemokine expres-
sion were examined to delineate inflammatory pathways
involved in the flaring mechanism in the model. Arthritis
was induced as described above and the injected and
contralateral ankles were excised post euthanasia at the
following time points: in flare 1 on days 1 (6 hr post i.a.
sensitization), 2, 3, 4 and in flare 2 on days 21 (6 hr post
i.v. challenge), 22, 24 and 27. Using the methods de-
scribed above, ankle joint homogenates were analyzed for
cytokine expression. We observed a significant up regula-
tion of the cytokines IL-6, IL1-β, MCP-1 and CINC-1 in
the local injected ankle joint in both flares 1 and 2 with
diverse temporal profiles. In flare 1, IL-1β peaked (253 ±
58 pg/ml; P < 0.001) on day 1 (6 hr post i.a. sensitization)
and continued to decline over the period of 4 days. IL-6
increased on day 1 (6 hr post i.a. sensitization) and
reached a peak (6720 ± 961 pg/ml; P < 0.001) on day 2.
MCP-1 peaked (171 ± 49 pg/ml; P < 0.001) on day 1 and
CINC-1 peaked (1870 ± 205 pg/ml; P < 0.001) on day 2 and
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Figure 1 (See legend on next page.)
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Figure 1 Establishment of the SCW mono-arthritic multi-flare model. (A) Inflammation of the ankle joint followed over a 29 day period after
administration of increasing doses (2.5 μg, 5 μg, or 10 μg) of SCW sensitization via i.a. delivery of antigen (day 1), followed by a systemic
challenge (fixed dose 100 μg) on day 21. Values are mean ± SEM of 8-11 rats per group. (B) Bioluminescence imaging comparing non-arthritic
and SCW rat ankle joint 6 hours following sensitization with 5 μg SCW. (C) Representative histomorphological sections of rat ankle joints collected
on day 29 following SCW sensitization comparing Non-Arthritic and SCW rat paw. Points of interest are Tarsus (Ta), Tibia (Ti), slight inflammation
(a), slight pannus (b), slight periosteal ossification (c), Synovium (S) and Articular cartilage (Ac). (D) Kinetics of cytokine expression in local injected
ankle joint. Protein exudates were extracted from non-arthritic and arthritic ankle joints at various time points following i.a. sensitization of 5 μg of
PGPS (Flare 1), and following systemic challenge of 100 μg PGPS (Flare 2). Levels of Interleukin 1 beta (IL-1β), Interleukin 6 (IL-6), Monocyte Chemotactic
Protein-1 (MCP-1) and Cytokine-Induced Neutrophil Chemoattractant (CINC) were evaluated (shown from top left to lower right respectively). Values
are mean ± SEM of 7-16 rats per group. δ Day 1 time point was at 6 hours post i.a. sensitization; α Day 21 time point was at 6 hours post i.v. challenge
(E) Simultaneous evaluation of pain and inflammation. A composite of 4 independent studies showing inflammation (ankle diameter; Y axis) and
pain (withdrawal threshold; Z axis) over time (days; X axis) following systemic i.v. challenge in Flare 2. Values are mean ± SEM of 6-8 rats per
group. ** = P < 0.01 versus Non-Arthritic; *** = P < 0.001 versus Non-Arthritic.
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(133 ± 16 pg/ml; P < 0.001) and IL-6 (4886 ± 599 pg/ml;
P < 0.001) on day 22, with a trend of decline on days
24 and 27. Both MCP-1 (115 ± 16 pg/ml; P < 0.001) and
CINC-1 (1304 ± 263 pg/ml; P < 0.001) expression peaked
on day 24 and declined to baseline by day 27 (Figure 1D).Simultaneous evaluation of pain (withdrawal threshold)
and inflammation (ankle diameter)
Using the von-Frey test for pain measurement, we sought
to align the model with clinical symptoms. We studied the
mechanical pain response elicited by the rats in flare 2.
Figure 1E illustrates the composite scores of inflammation
and pain from 4 independent studies. Pain response
assessed by withdrawal threshold (Z axis) is plotted versus
the inflammation measured by ankle diameter (Y axis)
for the same rats over days 21–29 following i.v. systemic
challenge of SCW (X axis). A robust and statistically
significant pain response was observed in SCW induced
rats reaching a peak between day 22–24 and persisting
through day 29 (P < 0.001), compared to non-arthritic
control rats. Furthermore, inflammation as assessed by
paw swelling, developed gradually, reaching a peak on
day 24 (P < 0.001) and showed a trend toward decline
on day 29. Taken together, the data suggests that pain
may precede inflammation and continue to persist up to
day 29, whereas inflammation starts to decline by day 29.
The robust inflammation (Δ ~2.0 mm) and pain (Δ ~20 g)
window between non-arthritic and SCW groups enabledTable 1 Cellular phenotyping of neutrophils and T cells in loc
Tissue Cell type Non-arthritic Flare
Ankle joint Neutrophils 3561
CD3+ T cells 1413
Lymph node Neutrophils BLQ
CD3+ T cells 9.1* 106
^The total number of cells in the injected ankle joint and lymph node compartmen
calculated from pooled tissue samples (n = 4 animals/group). BLQ: Below the Levelfurther pharmacological evaluation of compounds of
interest. The inflammation and pain response in the
contralateral paws of the SCW rats did not change
from their baseline values and the data was similar to
non-arthritic controls (data not shown).Effect of corticosteroid and analgesic therapy on
inflammation and pain (flare 2)
To further understand the pathogenic mechanisms amen-
able to drug treatment, we evaluated the effects of dexa-
methasone and buprenorphine on inflammation and
mechanical pain. Both dexamethasone (0.3 mg/kg/day)
and buprenorphine (0.05 mg/kg/day) were administered
once daily in the therapeutic regimen. Dexamethasone
administration resulted in the significant inhibition of paw
swelling by 95% (P < 0.001) and pain by 55% (P < 0.05)
compared to the SCW vehicle treated rats. On the other
hand, buprenorphine administration significantly inhibited
pain by 80% (P < 0.001) and did not have any effect on
paw swelling (0%) (Figure 2A-B).Etanercept inhibits inflammation and pain (flare 2)
To further investigate the role of TNF in the model, the
effect of etanercept was evaluated in flare 2. Etanercept
(0.25 mg/kg/day or 1 mg/kg/day) was administered in
both prophylactic (day 20, 24 hr prior to i.v. challenge)
and therapeutic (day 22, 24 hr after i.v. challenge)
regimens. In the prophylactic regimen, etanercept at
0.25 mg/kg significantly inhibited inflammation by 70%al and systemic compartments^
1 (24 hr post i.a. injection) Flare 2 (24 hr post i.v. injection)
6.4* 105 5.6* 104
1.6* 105 2.6* 104
BLQ BLQ
10.1* 106 19.9* 106
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Figure 2 Effect of corticosteroid and analgesic therapy on inflammation and pain (flare 2). (A) Ankle diameter post systemic i.v. challenge
followed until day 29 and (B) Paw withdrawal threshold values plotted for each group. Values are mean ± SEM of 8–11 rats per group. (T) therapeutic.
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http://www.biomedcentral.com/1471-2474/15/409(P < 0.001) and had a modest effect on mechanical pain
(37%; P < 0.05). The 1 mg/kg dose of etanercept sig-
nificantly inhibited inflammation by 76% (P < 0.001)
and reduced pain by 24%, compared to SCW vehicle
treated rats (Figure 3A-B; Table 2). Conversely, in thetherapeutic regimen, etanercept at 0.25 mg/kg and 1
mg/kg significantly inhibited inflammation by 44%
(P < 0.001) and 52% (P < 0.001) respectively, however
both the doses were ineffective in suppressing pain. Thera-
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i.v. challenge
D
Figure 3 Etanercept inhibits inflammation and pain in flare 2. (A) Effect on inflammation of etanercept administration at 0.25 mg/kg and 1
mg/kg when dosed prophylactically; (B) effect on mechanical pain. (C) Effect on inflammation of etanercept administration at 0.25 mg/kg and 1
mg/kg when dosed therapeutically; (D) effect on mechanical pain. Effect on inflammation of dexamethasone dosed therapeutically (C); effect on
pain (D). Values are mean ± SEM of 6–8 rats per group. (P) prophylactic; (T) therapeutic.
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http://www.biomedcentral.com/1471-2474/15/409(0.3 mg/kg/day) inhibited inflammation by 84% (P < 0.001)
and pain by 39% (P < 0.05) (Figure 3C-D; Table 2).
Etanercept inhibits production of cytokines IL-6, IL-1β,
MCP-1 and CINC-1 (flare 2)
As illustrated in Figure 4A-B, we ascertained the effect
of etanercept on the production of cytokines previ-
ously shown to be up-regulated in the model. A group
of SCW induced rats were administered a subcutane-
ous dose of etanercept (1 mg/kg/day) prophylactically
and were sacrificed on day 22, one day after the induction
of second flare. In the local ankle joint, we observed a sta-
tistically significant reduction in cytokine expression levels
of IL-1β (72%), IL-6 (83%), MCP-1 (77%) and CINC-1
(100%) with etanercept administration (P < 0.001). PositiveTable 2 Percentage inhibition in area under the curve values
inflammation and mechanical pain in flare 2 for the experime
Inflammation (ankle diame
Prophylactic Th
Etanercept 0.25 mg/kg 70% (P < 0.001) 44%
Etanercept 1.0 mg/kg 76% (P < 0.001) 52%
Dexamethasone nd 84%
*The values of statistical significance against SCW vehicle groups are represented in
SCW vehicle groups (P < 0.001). Values are calculated from 8–11 rats per group. ns:control dexamethasone (0.3 mg/kg/day) resulted in near
maximal suppression of the same cytokines (P < 0.001).
Induction of an additional flare (flare 3): evaluation of
inflammation and pain
We attempted to capture the chronic phase of the dis-
ease by extending the model to a third flare, by re-
challenging the SCW sensitized rats with a second i.v
challenge of SCW (flare 3). We observed that the in-
flammation in flare 3 (Δ 2 mm; P < 0.001) peaked on day
44 (72 hr post re-challenge), similar to inflammation
kinetics observed in flare 2. However, inflammation in
flare 3 continued to persist for 10 days until study ter-
mination on day 51 (Figure 5A). Figure 5B illustrates the
mechanical pain response in the sensitized paw. Similarnormalized to non-arthritic and SCW vehicle groups for
nt illustrated in Figure 3*
ter) Pain (withdrawal threshold)
erapeutic Prophylactic Therapeutic
(P < 0.001) 37% (P < 0.05) 0% (ns)
(P < 0.001) 24% (ns) 0% (ns)
(P < 0.001) nd 39% (P < 0.05)
parenthesis. In all cases, non-arthritic controls were significantly different from






























Etanercept 1 mg/kg (P)




































Etanercept 1 mg/kg (P)
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Figure 4 Etanercept inhibits production of cytokines IL-6, IL-1β, MCP-1 and CINC-1 in the arthritic paw (flare 2). (A) Effect of etanercept
(1 mg/kg prophylactically) on levels of Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6) and (B) Effect of etanercept (1 mg/kg prophylactically) on levels of
Monocyte Chemotactic Protein-1 (MCP-1) and Cytokine-Induced Neutrophil Chemoattractant-1 (CINC-1) from ankle joint homogenates collected on
day 22, 24 hours post induction of the flare 2. Values are mean ± SEM of 12–16 rats per group. * = P < 0.05 versus Non-Arthritic; *** = P < 0.001 versus
Non-Arthritic; ^^^ = P<0.001 versus SCW. (P) prophylactic; (T) therapeutic.
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http://www.biomedcentral.com/1471-2474/15/409to the kinetics of inflammation, the pain response fol-
lowing reactivation continued to increase significantly
and remained elevated throughout the 10 day period,
with a maximal response observed on day 45 (96 hr post
re-challenge) (P < 0.01). As anticipated non-arthritic con-
trol rats showed an increase in the pain response post
local i.a. sensitization with saline. However, systemic i.v.
injections had no effect on the pain in the non-arthritic
controls and the response was similar to their baseline
values. The cytokine expression profiles of IL-1β, IL-6,
MCP-1 and CINC-1, were similar to those observed in
flare 2 (data not shown).Comparative evaluation of repeated administration of
etanercept in both flares 2 and 3 versus administration in
flare 3 alone
Next, we compared the efficacy of etanercept (1 mg/kg/
day) in flare 2 versus flare 3, to delineate differences in
pathogenic mechanisms between the two flares. In addition,
we wanted to investigate whether prior treatment with eta-
nercept in flare 2 would have a sustained or improved effi-
cacy when re-administered in flare 3 with an intervening
drug washout period.
As depicted in Figure 6A, Cohort 1 received etaner-
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Figure 5 Induction of an additional flare (flare 3): evaluation of inflammation and pain. (A) Inflammation of the ankle joint following
intra-articular sensitization (day 1; flare 1), the first intravenous challenge (day 21; flare 2) and the second intravenous challenge (day 42; flare 3).
(B) Mechanical pain response (withdrawal threshold) in the same rats over the same time period. Values are mean ± SEM of n =8 rats per group.
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http://www.biomedcentral.com/1471-2474/15/409and was re-administered the same dose of etanercept in
flare 3. Conversely, Cohort 2 received etanercept in flare
3 only. In both the cohorts etanercept was administered
prophylactically one day prior to the induction of flare 2
or flare 3.
In Cohort 1 rats (flare 2) treatment with etanercept
suppressed inflammation by 56% (P < 0.001) and inhib-
ited mechanical pain by 44% (P < 0.01), as previously
observed. The rats treated with etanercept only in flare 3
(Cohort 2) showed 60% (P < 0.001) inhibition of inflam-
mation and a modest effect on pain (23%). Our data
suggests that when dosed in individual flares, the efficacy
of etanercept on inflammation and pain in flare 2 and 3
was comparable (Figure 6B-E).
We also investigated inflammation and pain in Cohort
1 rats that received etanercept treatments in both flare 2
and 3 with an intervening drug washout period of 14days. Interestingly, we observed a complete loss of eta-
nercept efficacy on both inflammation and pain upon
re-administration in flare 3 (Figure 6B-E). The loss of
efficacy upon re-administration of etanercept could be
due to potential immunogenicity as a result of antibody
production against etanercept, leading to its enhanced
clearance and consequently reduced systemic exposure.
To test this hypothesis we measured the circulating
levels (PK) of etanercept in serum at the termination of
the study on day 51. Circulating levels of etanercept
were below the levels of detection in these animals. In
contrast, pharmacologically efficacious levels of circulat-
ing etanercept (2.4 ± 1.5 ng/ml) were detected in rats
from Cohort 2 that had been treated in flare 3 only.
Positive control dexamethasone (0.3 mg/kg/day) signifi-
cantly inhibited inflammation and pain in both Cohorts




Figure 6 Effect of Etanercept in flares 2 and 3 versus administration in flare 3 alone. (A) A schematic representation of the dosing
paradigm for groups tested in the multi-flare model of SCW. Inflammation and pain values were recorded in all groups throughout the study.
Two separate cohorts underwent different dosing paradigms to investigate the response to single or repeated drug administration in each flare.
(B) Effect on inflammation of prophylactic administration of etanercept in cohorts 1 and 2; (C) Corresponding AUC calculations for inflammation.
(D) mechanical pain responses measured concurrently with inflammation in the same rats in cohorts 1 and 2. (E) Corresponding AUC calculations
for the pain response. Effect of prophylactic administration of dexamethasone on inflammation and pain in both cohorts (6B-E). Values are mean
± SEM of n= 8 rats per group. *** = P<0.001 versus Non-Arthritic; ^^ = P<0.01 versus SCW; ^^^ = P<0.001 versus SCW.
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http://www.biomedcentral.com/1471-2474/15/409control in both the cohorts had no effect on inflamma-
tion or pain and the data was similar to vehicle treated
SCW rats.
Discussion
RA is characterized by a complex interplay of various
pathogenic mechanisms leading to inflammation and
pain [47]. Animal models of arthritis can be effective
tools to investigate these mechanisms and delineate
pathways that might help predict the successful outcome
of novel therapeutics in the clinic. The previously
described mono-arthritic SCW model in rats captures
the relapsing and remitting flares of the disease, similar
to RA [35]. Typically, the model is characterized bytwo flares that resolve over time [37,48]. Intra-articular
injection of SCW antigen to local joint results in
mono-arthritis with inflammation limited only to the
sensitized joint, even after systemic challenge with the
antigen. The first flare induced by an intra-articular
injection of SCW results in mild paw swelling that
peaks 24 hrs post sensitization (flare 1) and resolves
over 72 hours. The second flare induced by an intra-
venous challenge with SCW (typically three weeks
later) results in a pronounced onset of paw swelling
reaching peak on day 3 after i.v. challenge (flare 2) and
resolves over a 5 day period. Previous studies by
Schimmer et al. [46], showed that the early phase of
the model can be triggered by Th2 cells and
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phils were involved in addition to T cells in the reacti-
vation of flares. In addition, the model is dependent on
multiple proinflammatory cytokines including TNF
and IL-1, as assessed by specific anti-cytokine therapy
and gene expression analysis [49,50]. In order to cap-
ture the chronic disease phenotype, we have developed
an extended version of the model with the induction of
an additional flare (flare 3). The third flare appears to
exhibit a chronic disease phenotype not previously
described. The mono-arthritic SCW model is a robust
model with reported incidence of arthritis in 90-100%
of the rats [34]. In line with literature, we were suc-
cessful in inducing arthritis in 100% of the animals in
all the three flares.
Histological assessment demonstrated that inflamma-
tion, pannus formation, degeneration of cartilage, perios-
teal bone formation, and/or bone resorption in SCW
rats was limited to the sensitized hind paw, there were
no histomorphologic findings in the proximal hind limb
joint tissues and the contralateral hind limb and hind
paw. We also observed that the gross histological dam-
age in the model was mild to moderate compared to
CIA or AA models and this is in agreement with current
literature [34,48]. An additional attractive feature of this
model, is that the disease severity and progression is less
severe when compared to other rodent models of arth-
ritis [34,38]. We observed that even in the extended flare
3, the disease was mild and the rats maintained a healthy
status throughout the course of the study.
Neutrophils have been shown to play a major role in
both flare 1 and 2. Depleting neutrophils by an anti-
neutrophil antibody has been shown to be efficacious in
the model [49]. Our results show the presence of neu-
trophils in flare 1 as determined by flow cytometry and
in flare 2 as assessed by histology. In addition to neutro-
phils, T cells also have been shown to contribute to the
pathogenesis of disease [38]. 24 hr post induction of
both flare 1 and 2, we observed an up regulation of T
cells in the ankle joint. The infiltrating T cells in the
local joint belonged to the CD4+ subpopulation, however
CD8+ T cells were not detected at this time-point. These
findings were also corroborated by histological analysis
of samples collected on day 29. A two fold increase in T
cells was observed in the draining lymph node, 24 hr
post induction of flare 2 compared to flare 1 and non-
arthritic controls (Table 1). We further characterized the
production of multiple proinflammatory cytokines and
showed increased levels of IL-1β, IL-6, MCP-1, CINC-1
in the local joint. The role of TNF, IL-1β, IL-6, MCP-1
and CINC-1 in the pathogenesis of SCW has been dem-
onstrated previously [50,51]. Moreover, neutralizing anti-
bodies to TNF, IL-1α/β and MCP-1 have been shown to
inhibit inflammation, thereby further confirming the roleof these cytokines in the model [46,49]. Although, we
expected to detect TNF in the arthritic joint homoge-
nates, this cytokine could not be quantified perhaps due
to its transient kinetics or the sensitivity of the assay. The
presence of IL-1β and IL-6 in the arthritic joint of SCW
rats and the role of these proinflammatory cytokines in in-
ducing pain in addition to inflammation in RA, led us to
investigate the kinetics of pain in our model [15,24,51].
In RA, pain experienced by patients involves the com-
plex interplay of nociceptive and inflammatory processes
[23]. Changes in joint pathology often result in an
increased sensitization of primary sensory neurons and
central sensitization, due to the changes in ascending or
descending modulatory pathways [52]. Physical changes in
the rheumatic joint (tissue edema, biochemical changes,
inflammatory mediators, nociceptor activation) all can
cause a decrease in the threshold for pain [53]. Further-
more, pain is an important clinical feature of RA and its
assessment is incorporated in the ACR scoring para-
digm [28]. The mono-arthritic SCW model allows us to
concurrently assess pain and inflammation following
drug intervention, facilitating the discovery of novel
anti-rheumatic agents. Simultaneous assessment of in-
flammation and pain has been previously described in
the polyarthritic mouse CIA model [54]. However, the
distinctive mono-arthritic phenotype of the SCW model
offers an advantage over the poly-arthritic models, as
we were able to monitor mechanical pain and inflam-
mation in the sensitized joint, with the contralateral
paw serving as an internal negative control.
To further characterize our model, we profiled a panel
of therapeutic agents such as, etanercept, dexametha-
sone and buprenorphine. We selected these agents based
on their established efficacy in other preclinical models
of arthritis [55-57]. The specific doses used for each
drug in these studies were selected based on multiple
dose response studies conducted internally (data not
shown). In flare 2, treatment with anti-TNF agent,
etanercept resulted in a significant inhibition of paw
swelling in both prophylactic and therapeutic regimens.
Interestingly, prophylactic treatment with etanercept
showed a modest decrease in mechanical pain, which
was statistically significant. However, therapeutic treat-
ment of etanercept had no effect on pain. Our data sug-
gests that TNF may play a bigger role in the onset and
progression of paw swelling, whereas other cytokines
such as IL-1β, IL-6, or other mechanisms in addition to
TNF, could also contribute to pain. Currently, efforts
are underway to further understand the roles of these
mechanisms in the multi-flare model pathophysiology.
Therapeutic treatment with corticosteroid dexametha-
sone was more effective in inhibiting paw swelling and
mechanical pain compared to etanercept. Prophylactic
administration of analgesic buprenorphine significantly
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together, these results suggest that inflammation and pain
can be distinguished and evaluated separately in the SCW
model. Histomorphological evaluation of the local joints
corroborated with the efficacy data, showing reduced
severity of inflammation and pannus formation after
treatment with etanercept and dexamethasone (data not
shown). Our internal data also show similar efficacy
profiles of etanercept and dexamethasone in the rat CIA
model on inflammation (data not shown).
We further extended the model to capture the chronic
phase of the disease (RA), by inducing an additional flare
via a second systemic antigen challenge of SCW, charac-
terizing both inflammation and pain. We observed that
inflammation and pain in flare 3 did not resolve by study
termination (10 days post induction of flare 3) resulting
in what appears to be a chronic phenotype. Interestingly,
the cytokine expression profile in the flare 3 was similar
to that observed in flare 2 with an up-regulation of
IL-1β, IL-6, MCP-1 and CINC-1.
The efficacy of etanercept in the chronic phase of the
model was also investigated. As observed in flare 2,
prophylactic treatment in flare 3 with etanercept re-
sulted in a significant inhibition of paw swelling, with
a modest impact on pain which was statistically not
significant. This data suggests that TNF may play simi-
lar role in flare 3. However, further investigation is
required to delineate additional mechanisms that may
be involved in the regulation of pain in this model.
Interestingly, the cohort of SCW treated rats that had
received etanercept treatment in flare 2, when treated
with the same dose of etanercept in flare 3, did not
respond to the treatment. The lack of efficacy observed
in flare 3 was attributed to the reduced systemic expos-
ure of etanercept in these rats most likely due to the im-
munogenicity. Immunogenicity toward certain biologics,
especially anti-TNF agents has been demonstrated in
rodents as well as in the clinic [58,59]. In addition,
multiple dosing of the agent may also contribute to the
generation of anti-drug antibodies [59]. Administration
of anti-TNF alone in RA patients can elicit autoanti-
bodies resulting in an enhanced clearance and loss of
efficacy of the agent [60]. Species specificity may also
contribute to the immunogenicity of biologic agents, as
observed with certain chimeric antibodies [61,62]. Inter-
estingly, co-administration of methotrexate (MTX),
along with certain anti-TNF agents, can reduce the im-
munogenicity and improve the efficacy of these agents
in the clinic [63]. Although the mechanisms involved in
the immunogenicity of biologic agents are not fully elu-
cidated, anti-TNF in combination with MTX is considered
to be a gold standard therapy for moderate to severe RA
patients [64]. Hence, it will be interesting to test etanercept
and MTX combination therapy compared to etanercepttreatment alone in flare 3. The flaring mechanism in the
SCW model allows for drug washout periods in between
compound administration. This might provide useful pre-
clinical insights on potential immunogenicity mechanisms
that may be relevant in a clinical setting.
Conclusions
In summary, we have described a novel extended mono-
arthritic SCW multi-flare model with an additional flare
that captures certain clinical aspects of RA. We report
for the first time that this model can be used to simul-
taneously evaluate mechanical pain and inflammation. In
addition, we have characterized our model to identify
various cytokines and cell types that could be key drivers
of disease in this model. Using etanercept we have dem-
onstrated that TNF plays a key role in the onset and
progression of paw swelling in the SCW model and can
also contribute to the development of pain. Based on
our studies, we report that this model provides a novel
tool for drug discovery to assess anti-rheumatic agents
targeting inflammation and pain.
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